Comparing an Immunotherapy Drug, Pembrolizumab With Chemotherapy in Advanced or Recurrent Endometrial Cancer
https://www.facingourrisk.org/research-clinical-trials/study/244/treatment-for-advanced-or-recurrent-endometrial-cancer
Clinicaltrials.gov identifier:
NCT05173987 (https://clinicaltrials.gov/show/NCT05173987)
Comparing an Immunotherapy Drug, Pembrolizumab With Chemotherapy in Advanced or Recurrent Endometrial Cancer
Study Contact Information:
For additional information, please contact: 1-888-577-8839, Brian Slomovitz at [email protected] or [email protected]
This study is being run by GOG and ENGOT.
About the Study
This study is to test the safety and effectiveness of treatment with pembrolizumab, also known as Keytruda, compared to a combination of chemotherapy treatments in women with deficient mismatch repair (dMMR) advanced or recurrent endometrial cancer who had not previously been treated with prior chemotherapy treatments. The study is being conducted to determine if pembrolizumab is better than the combined chemotherapy in terms of Progression Free Survival (PFS).
This study is no longer enrolling people.
What the Study Entails
The study involves two group:
Group 1:
Participants receive pembrolizumab on Day 1 of each cycle, which lasts 6 weeks, for up to 18 cycles (about 2 years) injected into the vein.
Group 2:
Participants receive a combination chemotherapy of carboplatin and paclitaxel on Day 1 of each 3-week cycle for 6 cycles (about 4 months) injected into the vein.
Study Sites
Arizona
- Phoenix
HonorHealth-USOR HonorHealth (Site 8000)
Contact: Study Coordinator (602) 406-7730
California
- La Jolla
Moores Cancer Center (Site 0037)
Contact: Study Coordinator (858) 822-6100 - Riverside
Kaiser Permanente Riverside Medical Center (Site 0045)
Contact: Study Coordinator (800) 398-3996
Connecticut
- New Haven
Smilow Cancer Center at Yale-New Haven (Site 0013)
Contact: Study Coordinator (203) 688-4242
Florida
- Miami Beach
Mount Sinai Cancer Center (Site 0018)
Contact: Study Coordinator (305) 674-2625 - Sarasota
Sarasota Memorial Hospital (Site 0005)
Contact: Study Coordinator (941) 917-2225
Georgia
- Atlanta
Northside Hospital (Site 0017)
Contact: Study Coordinator (404) 851-8000 - Newman
Southeastern Regional Medical Center
Contact: Study Coordinator (770) 400-6000
Illinois
- Zion
Midwestern Regional Medical Center, Inc (Site 0003)
Contact: Study Coordinator (847) 731-1777
Indiana
- Indianapolis
St. Vincent Hospital and Health Care Center, Inc (Site 0006)
Contact: Study Coordinator (317) 415-6740
Kentucky
- Lexington
Baptist Health Lexington (Site 0042)
Contact: Study Coordinator (502) 802-6829
Maryland
- Rockville
Maryland Oncology Hematology (Site 8002)
Contact: Study Coordinator (301) 933-3216
Massachusetts
- Worcester
University of Massachusetts Medical School - Division of Gynecologic Oncology (Site 0008)
Contact: Study Coordinator (508) 856-3216
Michigan
- Detroit
Karmanos Cancer Institute (Site 0029)
Contact: Study Coordinator (800) 526-6266
Mississippi
- Jackson
St. Dominic’s Hospital (Site 0024)
Contact: Study Coordinator (601) 200-4974
New Jersey
- Hackensack
John Theurer Cancer Center at Hackensack University Medical Center (Site 0026)
Contact: Study Coordinator (551) 996-5855
New York
- New York
The Blavatnik Family - Chelsea Medical Center at Mount Sinai (Site 0023)
Contact: Study Coordinator (212) 694-6000 - New York
Laura and Isaac Perlmutter Cancer Center at NYU Langone (Site 0016)
Contact: Study Coordinator (212) 731-6455 - New York
Icahn School of Medicine at Mount Sinai (Site 0052)
Contact: Study Coordinator (212) 241-6500 - New York
Memorial Sloan Kettering Cancer Center (Site 0009)
Contact: Study Coordinator (646) 888-4224
North Carolina
- Pinehurst
FirstHealth CLinical Trials (Site 0050)
Contact: Study Coordinator (910) 715-2200
North Dakota
- Bismark
Sanford Medical Center (Site 0054)
Contact: Study Coordinator (605) 376-4905 - Fargo
Sanford Fargo Medical Center - Roger Maris Cancer Center (Site 0055)
Contact: Study Coordinator (605) 376-4905
Ohio
- Cincinnati
University of Cincinnati Medical Center - University of Cincinnati Cancer Center (Site 0039)
Contact: Study Coordinator (513)584-7698 - Columbus
The James Cancer Hospital and Solove Research Institute at the Ohio State University Comprehensive Center
Contact: Study Coordinator (614) 293-3873
Oregon
- Portland
Providence Portland Medical Center (Site 0031)
Contact: Study Coordinator (503) 215-2614
Pennsylvania
- Philadelphia
Sidney Kimmel Cancer Center - Jefferson Health (Site 0053)
Contact: Study Coordinator (215) 481-4000 - Pittsburgh
University of Pittsburgh Medical Center Magee-Womens Hospital (Site 0034)
Contact: Study Coordinator (412) 642-5411 - Pittsburgh
AHN West Penn Hospital (Site 0011)
Contact: Study Coordinator (412) 330-6151 - Willow Grove
Asplundh Cancer Pavilion (Site 0014)
Contact: Study Coordinator (215) 481-4000
South Dakota
- Sioux Falls
Sanford Cancer Center - Gynecologic Oncology (Site 0002)
Contact: Study Coordinator (605) 312-3250
Texas
- Austin
Texas Oncology - Austin-USOR Texas Oncology (Site 8003)
Contact: Study Coordinator (512) 421-4250 - Dallas
Texas Oncology - Dallas-USOR Texas Oncology (Site 8005)
Contact: Study Coordinator (214)370-1000 - Tyler
Texas Oncology - Tyler-USOR Texas Oncology (Site 8004)
Contact: Study Coordinator (903) 579-9800
Virginia
- Richmond
VCU Health Adult Outpatient Pavillion (Site 0022)
Contact: Study Coordinator (804) 828-9080
This Study is Open To:
This study is no longer enrolling people.
This Study is Not Open To:
This study is no longer enrolling people.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.